Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

Q Shi, Y Wang, Q Hao, PO Vandvik, G Guyatt, J Li… - The Lancet, 2022 - thelancet.com
Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

[HTML][HTML] Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

M Chakhtoura, R Haber, M Ghezzawi, C Rhayem… - …, 2023 - thelancet.com
Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …

[HTML][HTML] Tirzepatide once weekly for the treatment of obesity

AM Jastreboff, LJ Aronne, NN Ahmad… - … England Journal of …, 2022 - Mass Medical Soc
Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

[HTML][HTML] Once-weekly semaglutide in adults with overweight or obesity

JPH Wilding, RL Batterham, S Calanna… - … England Journal of …, 2021 - Mass Medical Soc
Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical …

DM Rubino, FL Greenway, U Khalid, PM O'Neil… - Jama, 2022 - jamanetwork.com
Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like
peptide-1 analogues available for weight management. Objective To compare the efficacy …

[HTML][HTML] Signaling pathways in obesity: mechanisms and therapeutic interventions

X Wen, B Zhang, B Wu, H Xiao, Z Li, R Li… - Signal transduction and …, 2022 - nature.com
Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

[HTML][HTML] GLP-1 physiology informs the pharmacotherapy of obesity

DJ Drucker - Molecular metabolism, 2022 - Elsevier
Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications

S Sarma, S Sockalingam, S Dash - Diabetes, Obesity and …, 2021 - Wiley Online Library
Obesity is a chronic multisystem disease associated with increased morbidity and mortality.
The increasing prevalence of obesity makes it a major healthcare challenge across both …

[HTML][HTML] Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

TA Wadden, AM Chao, S Machineni, R Kushner… - Nature Medicine, 2023 - nature.com
The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Clinical management and treatment of obesity in China

Q Zeng, N Li, XF Pan, L Chen, A Pan - The lancet Diabetes & …, 2021 - thelancet.com
China has one of the largest populations with obesity in the world, and obesity has become
a major challenge for the country's health-care system. Current guidelines for obesity …